leadf
logo-loader
viewInnoCan Pharma

Innocan Pharma strikes deal to distribute its SHIR line of CBD beauty products in Italy and Switzerland

The distribution agreement with Cloud 9 Switzerland LLC will see it sell Innocan’s SHIR Beauty and Relief & Go lines in the two countries

InnoCan Pharma -
The deal marks Innocan's second distribution agreement in Europe

Innocan Pharma Corporation (CSE:INNO) said Thursday that it inked a deal to distribute its CBD line of beauty and pharmaceutical products in Italy and Switzerland.

The distribution agreement with Cloud 9 Switzerland LLC will see it sell Innocan’s SHIR Beauty and Relief & Go lines in the two countries, according to a release.

Iris Bincovich, Innocan’s CEO, expressed the company’s excitement to see its products distributed in Italy and Switerland.

READ: Innocan Pharma subsidiary inks manufacturing and distribution deal with Calgary cannabis producer Endless Sky

“This is the second distribution agreement we have signed in Europe,” Bincovich said in a statement. “I believe Cloud 9 will provide professional distribution of our SHIR and Relief & Go product lines."

Cloud 9 and its subsidiaries are active in the health and wellness sectors by developing, producing and commercialising hemp- and cannabis-based pharmaceuticals and nutraceuticals.

"In these extraordinary times, cannabis-based pharma and cosmetic products respond to consumers' desires for a more natural and healthy lifestyle,” Cloud 9’s managing director Dr Francis Scanlan said in a statement.

“Innocan has a proven high-level expertise and shared vision making them an ideal partner for us to develop these new markets.”

Also in Thursday’s statement, Innocan said it has engaged AGORACOM for a 12-month online marketing campaign to broaden its pool of potential investors. In consideration, Innocan will pay $75,000 worth of shares payable in five equal installments during the period from August 2020 to July 2021.  

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: InnoCan Pharma

Price: 0.29 CAD

CSE:INNO
Market: CSE
Market Cap: $50.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Innocan Pharma received U.S. FDA approval for their over the counter CBD...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has just received FDA approval in the United States for their patent-pending CBD Relief &GO pain relief collection. Bincovich talks about the collection and when they would...

on 07/20/2020

2 min read